.png){kind=icon}
.png){kind=icon}
Return
The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone
.png){kind=icon}
OA
AI
A
D
B
J
M
T
J
M
H
DOI：10.1002/bcp.70670.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Balcinrenone (previously AZD9977) is a novel selective non-steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment versus participants with normal hepatic function.
Keywords:
drug safety
heart failure
hepatic impairment
pharmacokinetics
Phase 1
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3
Papers:
8.5K
Citations:
1.8W
Organization
Cited Papers